Medical News

RSS

EC approves Nivestim for prevention of FN

Hospira announced today that the EC has approved Nivestim™ (filgrastim) for the prevention of FN, the most serious haematological toxicity that occurs as a result of cancer chemotherapy. Nivestim now has marketing authorisation in all EU member states. Nivestim is expected to reduce the cost of neutropenia treatment.

10 Jun 2010

FDA approves Endologix's expanded Powerlink stent graft product line

Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its expanded offering of Powerlink® stent graft products. The approval covers 31 new sizes of Powerlink® main body bifurcated, proximal extension, and limb extension stent grafts that increase the system's addressable patient population by 5% to 10%.

10 Jun 2010

CPL Biologicals completes construction of vaccine facility in Dholka, India

CPL Biologicals (CPLB), a joint venture of Cadila Pharmaceuticals Ltd. and Novavax, Inc., today announced that it has completed construction of its vaccine facility in Dholka, India and will commence equipment and installation validation this month so that the facility conforms to global standards for production of vaccines for human use.

10 Jun 2010

WaferGen announces microRNA, oncology gene panels for SmartChip Real-Time PCR System

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genetic analysis systems, today announced the availability of two gene expression profiling panels for the SmartChip Real-Time PCR System that will enable microRNA and cancer pathway profiling capability.

10 Jun 2010

Formedix's design tools integrated with Nextrials' EDC and clinical trial data management platform

Nextrials, Inc., a leader in clinical research software and services, today announced that its electronic data capture (EDC) and clinical trial data management platform, Prism™, is now integrated with the study design tools offered by Formedix. Formedix's industry leading Origin™ products include database design tools based on the data standards developed by the Clinical Data Interchange Standards Consortium (CDISC), a platform that Nextrials fully supports.

10 Jun 2010

BMEYE receives European Red Herring Top 100 Award

BMEYE B.V., the innovator of combined noninvasive, beat-to-beat blood pressure and cardiac output monitoring received the prestigious European Red Herring Top 100 Award 2010. Red Herring's Top 100 Europe list has become a mark of distinction for identifying promising new companies and entrepreneurs.

10 Jun 2010

Actelion Pharmaceuticals announces availability of PAH Mobile Reference Guide

Actelion Pharmaceuticals US, Inc. is announcing the availability of the Pulmonary Arterial Hypertension Mobile Reference Guide, the first multimedia smart phone application that provides information on PAH disease, pathology, diagnosis, and treatment guidelines to healthcare professionals.

10 Jun 2010

Idenix initiates IDX320 proof-of-concept study for HCV infection

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has initiated a 3-day proof-of-concept study of IDX320, a protease inhibitor for the treatment of hepatitis C virus (HCV) infection, under a Clinical Trial Application (CTA). The study is evaluating IDX320 in treatment-naive hepatitis C genotype 1-infected patients.

10 Jun 2010

Author Calvin Hill releases new book to share health and life-saving benefits of exercise program

Author Calvin Hill has released his new book Staying Fit after 60: Introducing the Exercise for Life Program to share the health and life-savings benefits of the program he has developed. He puts it bluntly: "I'm telling seniors, you can get old without feeling old."

10 Jun 2010

22 Midwest facilities named Centers of Excellence in accelerated partial breast irradiation

Twenty-two facilities in the Midwest have been named Centers of Excellence in accelerated partial breast irradiation (APBI) for their use of the SAVI® applicator, an advanced therapy for breast cancer as part of breast conservation therapy. The SAVI applicator can provide important advantages for women with early-stage breast cancer.

10 Jun 2010

Hooper Holmes' Heritage Labs division receives Certificate of Registration

Hooper Holmes today announced that its Heritage Labs division received a Certificate of Registration on May 28, 2010 and is now an ISO 13485:2003 registered company.

10 Jun 2010

$250 checks in the mail for Idaho Medicare beneficiaries in "Rx doughnut hole"

Older Idahoans living in fear of the cost of their next prescription drug may be getting some good news in the mail in the coming days; a $250 check to help. The checks are being mailed automatically to Idaho Medicare beneficiaries who fall into the dreaded Part D prescription drug coverage gap know as the "doughnut hole" – which leaves many stuck paying full price for their drugs, a cost many simply can't afford.

10 Jun 2010

Researchers develop new computer program for early diagnosis of Alzheimer's disease

Researchers of the University of Granada have developed a new computer program that allows early diagnosis of Alzheimer's disease through processed images. This new system has enhanced successful early diagnosis of Alzheimer's disease up to 90%, which is an important progress within this area of study.

10 Jun 2010

Onset Therapeutics expands sales force by over 50% in 2010

Onset Therapeutics, a specialty pharmaceutical company focused in dermatology, today announced the completion of the Company's latest sales force expansion initiative designed to provide national dermatology coverage to support the success of two recently launched products and the Company's rapidly growing pipeline of products in various stages of development.

10 Jun 2010

Quark Pharmaceuticals closes $10M private financing round

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the closing of a private financing by the existing investors of Quark totaling an aggregate of $10 million. The investors are funds of the prestigious SBI Holdings Group in Japan. In connection with the financing, Mr. Yoshitaka Kitao, CEO of SBI Holdings, Inc. and Mr. Robert Takeuchi, Director of SBI Investment Co., Ltd. will become members of the Quark board of directors.

10 Jun 2010

FDA grants Collegium Fast Track designation for COL-172 opioid formulation

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of COL-172 for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time.

10 Jun 2010

Raw and cooked gingers reduce pain associated with muscle injury by 24%: Reed's

Reed's, Inc., maker of the top-selling sodas in natural food stores nationwide, commented today on a recent study in The Journal of Medicine that both raw and cooked ginger reduce pain associated with muscle injury by about 24%, compared with placebo. The study was supported by the McCormick Science Institute.

10 Jun 2010

Boston Scientific's TAXUS Element Paclitaxel-Eluting Coronary Stent System launched in Europe

Boston Scientific Corporation today announced the market launch and first implants of its TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System in the European Union and other CE Mark countries. The TAXUS Element Stent System is the Company's third-generation drug-eluting stent (DES) technology and incorporates a platinum chromium alloy with an innovative stent design and an advanced catheter delivery system. It received CE Mark approval last month, which included a specific indication for the treatment of diabetic patients.

10 Jun 2010

StemCells' GS2-M cell culture media formulation enhances pluripotency of human ES, iPS cells

StemCells, Inc. announced today that newly published independent research demonstrates that its GS2-M cell culture media formulation enhances the pluripotency of human embryonic stem and induced pluripotent stem cells. The Company's GS2-M medium has already been shown to enable the derivation and long-term maintenance of mouse iPS cells.

10 Jun 2010

Elsevier announces acquisition of Collexis

Elsevier, the leading global publisher of scientific, technical, and medical information products and services, announced today the acquisition of assets from Collexis Holdings, Inc., a leading developer of semantic technology and knowledge discovery software.

10 Jun 2010